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cells, and total lymphocyte counts along with platelet
counts e account for the majority of variability in IR in this
cohort. CD4-CD8- T cells and NKT cells may be emerging
biomarkers of chronic GVHD activity. Lymphocyte activation
without overt GVHD adds to the complexity of the study of
post-HCT IR. Withmore patient data, predictive classiﬁcation
of GVHD status by peripheral blood cell subset testing may
become possible.Table
Factor and Discriminant Analysis
Factor Percent
of Data
Variance
Cumulative
Percent
of Variance
Cumulative
Percent
Misclassiﬁed
on DA
Cumulative
P
Factor 1 (CD4+,
CD8+, CD45RO- T
cells subsets)
33.91 33.91 41.9 0.54
Factor 2 (naïve B
and switched
memory B cell
subsets)
28.19 62.10 35.0 0.10
Factor 3 (ALC +
platelet count)
25.54 87.65 13.3 0.06367
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Background: Allogeneic hematopoietic cell transplantation
(HCT) can be curative in patients with acute myeloid
leukemia (AML), but relapse after HCT continues to be
a leading cause of mortality. Treatment options for these
patients are limited. Hypomethylating (HM) agents such as
5-azacytidine and 5-aza-2'-deoxycytidine (gemcitabine)
have immunomodulatory properties including augmenting
tumor antigen presentation that may enhance graft-versus-
leukemia (GVL) effect. Moreover, inhibitory effects of these
agents on T-cell activation and cytokine production may lead
to low incidence of graft-versus-host-disease (GVHD). Our
aim was to describe the outcomes, including response,
survival, and incidence of GVHD, in patients treated with HM
agents for relapsed AML or loss of donor chimerism (LDC)
after HCT.
Methods: Subjects were patients with relapsed AML or LDC
after allogeneic HCT for AML or high-risk myelodysplastic
syndrome (MDS) whowere treatedwith either 5-azacytidine
or decitabine at the University of Pittsburgh Cancer Institute.
Relapse was deﬁned as a period of complete remission (CR)
after HCT followed by re-occurrence of>5%myeloid blasts or
cytogenetic abnormalities on bone marrow biopsy. LDC was
deﬁned as <100% donor chimerism without relapse. Retro-
spective analysis was performed to determine response to
HM agents, overall survival from time of relapse or LDC, and
incidence of GVHD.
Results: Thirteen patients were identiﬁed, whose median
age was 57 years (22-62), and median time to relapse after
HCT was 124 days (30 to 847). Seven patients receivedmyeloablative conditioning regimens, and 6 patients
received reduced-intensity conditioning. Nine patients had
relapsed AML, and 4 patients had LDC. Ten patients were
treated with decitabine and 3 patients were treated with 5-
azacytidine, with median cycles received of 4 (1-9). After
hypomethylating agents, 9 of 12 (75%) evaluable patients had
a CR, and 3 patients had progressive disease. Eight of 10 (80%)
evaluable bone marrow biopsies revealed 100% donor
chimerism after treatment with a HM agent. Grade I-IV acute
GVHD of the liver occurred in 6 patients, 3 of whom had
isolated liver involvement. Median survival was 308 days
(44-857) from time of relapse or LDC, and 7 patients are alive
at time of analysis and remain in CR.
Conclusions: HM agents in patients with relapsed AML can
be effective in reversing loss of donor chimerism and
inducing CR. This may be due to epigenetic changes and
subsequent immunomodulatory effects that enhance GVL
effect. There may be a relationship between use of these
agents with development of acute liver GVHD, and further
exploration into pathophysiology and predisposing factors
are warranted. The use of HM agents as a maintenance
strategy in patients at high risk of relapse after HCT should be
further explored.368
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Background: The Hematopoietic Cell Transplantation
Comorbidity Index (HCT-CI) is predictive of non-relapse
mortality (NRM) and overall survival (OS) after allogeneic
stem cell transplant (SCT). However, the HCT-CI has been less
well validated in the older SCT patient population. We
hypothesized that the HCT-CI could have less discriminative
ability in this population, where multiple comorbidities are
common.
Methods: We performed a retrospective study of patients
50 years of age who underwent SCT at UCSF, where HCT-CI
was recorded prospectively as part of routine clinical care
starting in 2007. Outcomes measured included NRM and OS,
as well as grade 3-4 non-hematologic adverse events to 100
days post-SCT, duration of hospital stay, and risk of re-
hospitalization with the ﬁrst 100 days. Kaplan Meier
methods with log-rank tests were used for analysis of NRM
and OS; Student's t test or chi-square test were used for the
remaining outcome measures.
Results: We identiﬁed 59 patients 50 years of age with
complete HCT-CI data. The median age was 60 years (range
50-74) and 31 (53%) of the patients were male. Most SCTs
were for AML (n¼30, 51%) orMDS (n¼9,15%). SCTswere non-
myeloablative in 24 patients (41%) and conditioning was
ﬂudarabine/busulfan-based in 53 patients (90%). Median
follow up was 22 months.
Twelve patients had HCT-CI score of 0 (20%), 19 had HCT-
CI score of 1-2 (32%) and 28 had HCT-CI score 3 (47%). High
HCT-CI score (3) was associated with signiﬁcantly
decreased OS (median OS not reached for HCT-CI 0-2 vs 14
months for HCT-CI 3; hazard ratio 2.2, P ¼ .02). This
remained signiﬁcant in multivariate analysis that included
age, KPS, treatment intensity, and the presence or absence of
